Kryxana® (Ribociclib) — CDK4/6 Inhibitor With the Most Comprehensive Overall Survival Evidence in HR-Positive Breast Cancer

The Only CDK4/6 Inhibitor With Proven OS Benefit in Premenopausal Women — Three Phase 3 Trials Demonstrating Significant Survival Improvement

Kryxana® (Ribociclib) is a selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor used in combination with endocrine therapy for hormone receptor-positive (HR+) HER2-negative locally advanced or metastatic breast cancer — in pre/perimenopausal and postmenopausal women. Ribociclib inhibits CDK4 and CDK6 — preventing phosphorylation of the retinoblastoma protein (Rb) and blocking cell cycle progression from G1 to S phase — arresting HR-positive breast cancer cell proliferation.

Kryxana is distinguished from the other CDK4/6 inhibitors by the most comprehensive overall survival evidence in the class. Three landmark Phase 3 trials — MONALEESA-2, MONALEESA-3, and MONALEESA-7 — all demonstrate significant OS benefit with Ribociclib across different patient populations:

• MONALEESA-2 — OS benefit in first-line postmenopausal HR+ metastatic breast cancer with aromatase inhibitor
• MONALEESA-3 — OS benefit in first and second-line postmenopausal with Fulvestrant — median OS 53.7 months
• MONALEESA-7 — OS benefit specifically in premenopausal women — the first and only CDK4/6 inhibitor trial to demonstrate OS benefit in premenopausal patients — median OS not reached at 42 months vs 40.9 months for placebo

This breadth of OS evidence across both pre/perimenopausal and postmenopausal women — and across first and second-line treatment — makes Kryxana the CDK4/6 inhibitor with the strongest and most comprehensive overall survival data in HR-positive metastatic breast cancer.

A.K. Pharma is a trusted medicine distributor in Delhi supplying genuine Kryxana (Ribociclib) to hospitals, oncology centres, breast cancer clinics, and pharmacies across India. Manufactured by Novartis, Kryxana is an essential medicine in modern breast cancer oncology — changing the treatment paradigm for HR-positive metastatic breast cancer globally.

---

What is Kryxana (Ribociclib)?

Kryxana contains Ribociclib — a selective, small molecule CDK4/6 inhibitor that competitively binds to the ATP-binding site of CDK4 and CDK6 kinases — blocking their catalytic activity and preventing downstream Rb phosphorylation and cell cycle progression.

The CDK4/6-Rb-E2F Axis — Central Driver of HR-Positive Breast Cancer Proliferation:

In normal cells, cell cycle progression from G1 to S phase is tightly regulated by:

1. Growth factors → cyclin D1 upregulation → cyclin D1 binds CDK4/CDK6
2. Cyclin D-CDK4/6 complexes phosphorylate Rb → Rb releases E2F transcription factors
3. E2F activates S-phase genes → DNA replication and cell division

In HR-positive breast cancer:

• Estrogen signalling → drives cyclin D1 overexpression → constitutive CDK4/6 activation
• CDK4/6 gene amplification — in a subset of tumours
• CCND1 (cyclin D1) amplification — driving hyperactive CDK4/6-cyclin D1 complexes
• Result: constitutive Rb phosphorylation → uncontrolled E2F activation → continuous cell cycle progression → uncontrolled proliferation

Ribociclib’s Mechanism: Ribociclib competitively inhibits ATP binding to CDK4 and CDK6 — without ATP, CDK4/6 cannot phosphorylate Rb. Hypophosphorylated Rb remains bound to E2F → E2F target genes are not transcribed → G1 cell cycle arrest → HR-positive breast cancer cell proliferation is blocked.

Synergy With Endocrine Therapy: Ribociclib and endocrine therapies (aromatase inhibitors, Fulvestrant) act synergistically — endocrine therapy reduces cyclin D1 expression (less CDK4/6 substrate) while Ribociclib directly inhibits CDK4/6. Dual targeting of both upstream (via reduced cyclin D1) and downstream (via direct CDK4/6 inhibition) components of the same pathway provides more complete cell cycle blockade — translating to significantly longer PFS and OS than endocrine therapy alone.

Full prescribing information is available at the FDA label for Ribociclib.

---

Clinical Studies and Evidence

MONALEESA-2 Trial (Ribociclib + Letrozole — First-Line Postmenopausal) Published in the New England Journal of Medicine (2016) with updated OS analysis published in Annals of Oncology (2021), MONALEESA-2 was a Phase 3 randomised controlled trial of 668 postmenopausal women with HR-positive HER2-negative locally advanced or metastatic breast cancer who had not received prior systemic therapy for metastatic disease — comparing Ribociclib + Letrozole vs placebo + Letrozole. Key results at final OS analysis:

• Progression-free survival — median PFS 25.3 months (Ribociclib + Letrozole) vs 16.0 months (Letrozole alone) — HR 0.568 — significantly improved
• Overall survival — median OS 63.9 months (Ribociclib + Letrozole) vs 51.4 months (Letrozole alone) — HR 0.76 — significantly improved — a 12.5-month median OS benefit
• 5-year OS rate — 52.4% (Ribociclib + Letrozole) vs 43.7% (Letrozole alone)
• Established Ribociclib + aromatase inhibitor as a first-line standard of care for postmenopausal HR-positive HER2-negative metastatic breast cancer — with proven OS benefit

MONALEESA-7 Trial (Ribociclib + Endocrine Therapy — Premenopausal Women) Published in the New England Journal of Medicine (2018) for PFS data and Annals of Oncology (2023) for updated OS data, MONALEESA-7 was a Phase 3 randomised controlled trial of 672 pre/perimenopausal women with HR-positive HER2-negative advanced breast cancer — comparing Ribociclib + endocrine therapy (Tamoxifen or NSAI + Goserelin) vs placebo + endocrine therapy. Key results at final OS analysis:

• Progression-free survival — median PFS 23.8 months (Ribociclib) vs 13.0 months (placebo) — HR 0.553 — significantly improved
• Overall survival — median OS not reached (Ribociclib) vs 40.9 months (placebo) — HR 0.763 — significantly improved — the first and only CDK4/6 inhibitor trial to demonstrate significant OS benefit specifically in premenopausal women
• 5-year OS rate — 54.2% (Ribociclib) vs 44.0% (placebo)
• This OS benefit in premenopausal women is clinically landmark — premenopausal HR-positive metastatic breast cancer affects younger women with different biology, greater disease burden, and longer remaining life expectancy — the demonstration of OS benefit in this population was a paradigm shift

MONALEESA-3 Trial (Ribociclib + Fulvestrant — First and Second-Line Postmenopausal) Published in the New England Journal of Medicine (2018) with final OS analysis published in New England Journal of Medicine (2021), MONALEESA-3 enrolled 726 postmenopausal women with HR-positive HER2-negative advanced breast cancer — both first-line and second-line (after prior endocrine therapy) — comparing Ribociclib + Fulvestrant (Faslodex) vs placebo + Fulvestrant. Key results at final OS analysis:

• Progression-free survival — median PFS 20.5 months (Ribociclib + Fulvestrant) vs 12.8 months (Fulvestrant alone) — HR 0.587 — significantly improved
• Overall survival — median OS 53.7 months (Ribociclib + Fulvestrant) vs 41.5 months (Fulvestrant alone) — HR 0.726 — significantly improved — a 12.2-month median OS benefit
• The 53.7-month median OS in the Ribociclib + Fulvestrant arm represents one of the longest median OS values ever demonstrated for a CDK4/6 inhibitor + endocrine combination in HR-positive metastatic breast cancer
• Established Ribociclib + Fulvestrant as a standard of care option across first and second-line postmenopausal HR-positive metastatic breast cancer with proven OS benefit

MONALEESA-2 — Early Stage Breast Cancer Signal (Emerging Data) Emerging data from ongoing adjuvant trials investigating Ribociclib in early breast cancer are being monitored — though unlike Ramiven (Abemaciclib) which has approved adjuvant indication (monarchE), Ribociclib does not currently have an approved adjuvant indication.

---

Available Strengths

Kryxana is available as:

Standard dose: 600mg (three 200mg tablets) orally once daily for 21 days followed by 7 days off — repeating in 28-day cycles.

The 63-tablet pack provides exactly one cycle of treatment (21 days × 3 tablets = 63 tablets) — simplifying dispensing and supply management.

---

Indications — What Kryxana is Used For

HR-Positive HER2-Negative Advanced or Metastatic Breast Cancer — Postmenopausal Women:

• In combination with an aromatase inhibitor (Letrozole or Anastrozole) as initial endocrine-based therapy — first-line (MONALEESA-2)
• In combination with Fulvestrant (Faslodex) as initial endocrine-based therapy or after prior endocrine therapy — first and second-line (MONALEESA-3)

HR-Positive HER2-Negative Advanced or Metastatic Breast Cancer — Pre/Perimenopausal Women:

• In combination with endocrine therapy (Tamoxifen or aromatase inhibitor) plus ovarian function suppression (GnRH agonist such as Zoladex/Goserelin) — first-line (MONALEESA-7)
• The only CDK4/6 inhibitor with proven OS benefit specifically in premenopausal women

For detailed indication information refer to MedlinePlus Ribociclib.

---

Key Benefits of Kryxana

Most Comprehensive OS Evidence Among CDK4/6 Inhibitors Kryxana is the only CDK4/6 inhibitor to demonstrate significant overall survival benefit in three separate Phase 3 trials — MONALEESA-2, MONALEESA-3, and MONALEESA-7 — across first and second-line settings, and across both postmenopausal and premenopausal women. No other CDK4/6 inhibitor has demonstrated OS benefit across this breadth of patient populations and treatment settings.

Unique OS Benefit in Premenopausal Women MONALEESA-7 is the only clinical trial in any CDK4/6 inhibitor programme to demonstrate significant OS benefit specifically in premenopausal women with HR-positive metastatic breast cancer. This is a critically important finding — premenopausal HR-positive metastatic breast cancer affects younger women who stand to benefit most from proven life extension. Kryxana is the preferred CDK4/6 inhibitor in premenopausal HR-positive metastatic breast cancer based on this unique OS evidence.

Longest Median OS in Second-Line HR-Positive MBC The MONALEESA-3 final OS analysis demonstrates a median OS of 53.7 months with Ribociclib + Fulvestrant — one of the longest median OS values ever demonstrated in a Phase 3 trial for HR-positive metastatic breast cancer in any treatment line. This remarkable survival outcome reflects the transformative impact of optimal CDK4/6 inhibitor + endocrine therapy on long-term prognosis.

Flexible Combination Partners — AI or Fulvestrant Kryxana can be combined with aromatase inhibitors (MONALEESA-2) or Fulvestrant (MONALEESA-3) — both available from A.K. Pharma — providing flexibility across first and second-line settings and different endocrine resistance profiles. This versatility ensures Kryxana can be used throughout the metastatic treatment continuum.

Comprehensive Premenopausal Coverage With OFS MONALEESA-7 specifically studied Ribociclib with both Tamoxifen + OFS and NSAI + OFS — providing evidence for Kryxana across both endocrine combination options in premenopausal women. This comprehensiveness makes Kryxana applicable in premenopausal patients regardless of which endocrine partner is chosen.

3-Weeks-On/1-Week-Off Schedule — Structured Treatment Cycles The 21-day on / 7-day off dosing schedule provides a structured weekly break allowing haematological toxicity recovery between cycles — particularly the neutropenia that is the primary dose-limiting toxicity of CDK4/6 inhibitors. The predictable cycle structure simplifies monitoring and patient management.

Convenient 63-Tablet Pack — One Pack Per Cycle The 63-tablet pack contains exactly one 28-day cycle of treatment — simplifying dispensing, adherence tracking, and supply management for patients, pharmacies, and hospital formularies.

---

How Kryxana Works — CDK4/6 Inhibition in HR-Positive Breast Cancer

Normal Cell Cycle Regulation:

The cell cycle is tightly regulated by cyclins and cyclin-dependent kinases (CDKs). The G1 to S phase transition — the commitment point for cell division — is controlled by:

1. Mitogenic signals (growth factors, estrogen in breast cancer) → cyclin D1 induction
2. Cyclin D1 binds CDK4 and CDK6 → activates CDK4/6 kinase activity
3. Activated CDK4/6-cyclin D1 complexes phosphorylate Rb protein (pRb) → multi-site Rb hyperphosphorylation
4. Hyperphosphorylated Rb releases E2F transcription factors from sequestration
5. Free E2F factors activate transcription of S-phase genes (cyclin E, PCNA, dihydrofolate reductase, DNA polymerase alpha, etc.)
6. Cell enters S phase → DNA replication → cell division

Dysregulation in HR-Positive Breast Cancer:

In HR-positive breast cancer, the CDK4/6-Rb-E2F axis is hyperactivated through:

• Estrogen receptor activation → cyclin D1 transcription → cyclin D1 protein overexpression
• CCND1 gene amplification (chromosome 11q13) → in ~15-20% of HR-positive breast cancers
• CDK4/CDK6 gene amplification — less common but present in some tumours
• Loss of p16INK4a (CDKN2A) — natural CDK4/6 inhibitor — silenced in many breast cancers
• Combined effect — CDK4/6 are constitutively hyperactive → continuous Rb hyperphosphorylation → uncontrolled E2F-driven proliferation

Ribociclib’s Mechanism:

Step 1 — Competitive ATP Binding Inhibition: Ribociclib binds competitively to the ATP-binding pocket of CDK4 and CDK6 — preventing ATP from binding. Without ATP, the CDK4/6 kinase cannot phosphorylate substrate proteins.

Step 2 — Rb Hypophosphorylation: Without CDK4/6 activity, Rb remains in its hypophosphorylated (active) state — bound to E2F transcription factors — sequestering them and preventing E2F-driven transcription.

Step 3 — G1 Cell Cycle Arrest: Without E2F activation, S-phase genes are not transcribed → cells cannot progress from G1 to S phase → G1 cell cycle arrest. HR-positive breast cancer cells arrest in G1 — accumulating in a growth-arrested state.

Step 4 — Cellular Senescence: Prolonged G1 arrest with CDK4/6 inhibition leads to cellular senescence — a stable, irreversible growth arrest state — in a significant proportion of cells. Senescent cells upregulate the SASP (Senescence-Associated Secretory Phenotype) which may have immunogenic and anti-tumour effects — contributing to durable responses beyond simple cytostasis.

Synergistic Mechanism With Endocrine Therapy:

Endocrine therapies reduce cyclin D1 expression by suppressing ER-driven CCND1 transcription → less cyclin D1 available → less CDK4/6 activation. Ribociclib simultaneously blocks the CDK4/6 that is present from phosphorylating Rb. The combination creates:

• Reduced CDK4/6-cyclin D1 complex formation (endocrine therapy)
• Inhibition of residual CDK4/6-cyclin D1 complexes (Ribociclib)
• More complete Rb dephosphorylation → more complete G1 arrest → more durable cell cycle suppression

For detailed mechanism overview refer to ESMO Breast Cancer Guidelines and ASCO Breast Cancer Guidelines.

---

Kryxana vs Palbace vs Ramiven — CDK4/6 Inhibitor Comparison

---

Dosage and Administration

Standard Dose:

• 600mg (three 200mg tablets) orally once daily for 21 days
• Followed by 7 days off — completing a 28-day cycle
• Continue cycling until disease progression or unacceptable toxicity
• Take at approximately the same time each day — with or without food

Important — Take With or Without Food Consistently: Food has a modest effect on Ribociclib absorption — taking consistently with food or consistently without food avoids day-to-day variability. Avoid grapefruit and grapefruit juice — CYP3A4 inhibition increases Ribociclib levels significantly.

Administration:

• Swallow tablets whole — do not crush, chew, or split
• If a dose is missed — skip if within 12 hours of next scheduled dose; take if more than 12 hours remain

When Used With Endocrine Therapy Partners:

• Aromatase inhibitor (first-line): Letrozole 2.5mg once daily or Anastrozole 1mg once daily — continuously throughout all cycles
• Fulvestrant (first and second-line): 500mg IM on days 1, 15, 29 then every 28 days — per standard Fulvestrant schedule
• Pre/perimenopausal + OFS: Add Zoladex (Goserelin) 3.6mg SC every 28 days — begin at least 4 weeks before starting Ribociclib to ensure suppression of ovarian function

Dose Reduction Schedule:

• Starting dose: 600mg once daily (three 200mg tablets)
• First reduction: 400mg once daily (two 200mg tablets)
• Second reduction: 200mg once daily (one 200mg tablet)
• If 200mg not tolerated — permanently discontinue

Monitoring Schedule:

Full dosing guidelines available at Drugs.com Ribociclib Dosage.

---

QTc Monitoring — Important Safety Requirement Unique to Ribociclib

Ribociclib prolongs the QTc interval — a unique safety consideration among CDK4/6 inhibitors. QTc prolongation requires careful management:

Before Starting Kryxana:

• ECG at baseline — do NOT start if QTc >450ms at baseline
• Correct electrolyte abnormalities (hypokalaemia, hypomagnesaemia, hypocalcaemia) — all prolong QTc

During Treatment:

• ECG at Day 14 of Cycle 1 (when QTc prolongation is most likely to occur)
• ECG at Day 1 of Cycle 2
• Repeat ECG if QTc >450ms

QTc Management:

• QTc 450-480ms — maintain dose; repeat ECG within 48 hours
• QTc >480ms — withhold Ribociclib; repeat ECG within 48 hours; correct electrolytes; restart at reduced dose when QTc <481ms
• QTc >500ms or >60ms increase from baseline — permanently discontinue

Drugs to Avoid With Ribociclib:

• Anti-arrhythmics (amiodarone, sotalol, quinidine)
• Some antibiotics (erythromycin, clarithromycin — also CYP3A4 inhibitors)
• Haloperidol, methadone, domperidone
• Any drug that prolongs QTc — check interaction database before prescribing

This QTc monitoring requirement is the primary safety distinction between Kryxana and the other CDK4/6 inhibitors — Palbociclib and Abemaciclib do not have significant QTc effects.

---

Who Should Use Kryxana

Kryxana is prescribed for:

Postmenopausal women:

• HR-positive HER2-negative locally advanced or metastatic breast cancer — first-line with aromatase inhibitor (MONALEESA-2)
• HR-positive HER2-negative advanced breast cancer — first or second-line with Fulvestrant (MONALEESA-3)
• Patients where proven OS benefit with Ribociclib specifically is the clinical priority

Pre/Perimenopausal women:

• HR-positive HER2-negative advanced breast cancer — first-line with endocrine therapy + OFS (MONALEESA-7)
• Kryxana is the preferred CDK4/6 inhibitor for premenopausal women — the only CDK4/6 inhibitor with proven OS benefit in this population
• Requires concurrent ovarian function suppression with GnRH agonist (Zoladex/Goserelin) — available from A.K. Pharma

Patients where QTc monitoring is feasible:

• Kryxana requires ECG monitoring for QTc — facilities must be able to perform ECG monitoring on the required schedule

Kryxana is prescribed by medical oncologists and breast cancer specialists. A.K. Pharma supplies Kryxana to hospitals, oncology centres, breast cancer clinics, and pharmacies across Delhi and India.

---

Possible Side Effects

Common side effects include neutropenia (74% — most common dose-limiting toxicity), nausea (52%), fatigue (37%), diarrhoea (35%), leukopenia (33%), alopecia (33%), vomiting (29%), constipation (25%), headache (22%), and back pain (20%).

Serious side effects include:

Neutropenia: Grade 3-4 neutropenia in approximately 60% of patients — the most important haematological toxicity. CBC monitoring per schedule is mandatory. Dose delay for Grade ≥3 neutropenia; dose reduce for recurrent Grade ≥3 or febrile neutropenia. Febrile neutropenia is uncommon (approximately 1.5%) despite high rates of Grade 3-4 neutropenia — patients tolerate the neutropenia well in most cases.

QTc Prolongation: Grade 3 QTc prolongation (>500ms) in approximately 3.3% of patients. Mandatory ECG monitoring schedule — see QTc monitoring section above. Permanently discontinue for QTc >500ms.

Hepatotoxicity: Grade 3-4 ALT/AST elevation in approximately 10% — LFT monitoring required every 2 cycles for first 6 cycles.

Interstitial Lung Disease/Pneumonitis: Rare but reported — monitor for new respiratory symptoms; withhold and evaluate if suspected.

Embryo-Foetal Toxicity: Ribociclib can cause foetal harm. Effective contraception required during treatment and for 3 weeks after last dose. Pregnancy test before starting in women of reproductive potential.

Full side effect information available at FDA Ribociclib Safety Information.

---

Precautions

• QTc monitoring — mandatory ECG at baseline, Day 14 Cycle 1, Day 1 Cycle 2; correct electrolytes before starting; avoid QTc-prolonging medications
• Neutropenia monitoring — CBC on schedule; dose delay/reduction per protocol
• LFT monitoring — every 2 cycles for first 6 cycles; dose reduce for significant elevation
• Grapefruit — avoid; strong CYP3A4 inhibition significantly increases Ribociclib exposure
• Strong CYP3A4 inhibitors — avoid (ketoconazole, clarithromycin, ritonavir); if unavoidable reduce Ribociclib dose to 400mg daily
• Strong CYP3A4 inducers — avoid (rifampicin, phenytoin, carbamazepine, St John’s Wort); reduce Ribociclib efficacy
• Premenopausal women — must confirm adequate ovarian suppression with GnRH agonist; Ribociclib + endocrine therapy is not adequate without confirmed OFS
• Pregnancy — teratogenic; effective contraception mandatory during and for 3 weeks after treatment
• Breastfeeding — discontinue during treatment and for 3 weeks after last dose
• Refer to ESMO Breast Cancer Guidelines for complete management context

---

Storage and Handling

• Store at room temperature below 30°C
• Keep in original packaging — protect from moisture and light
• Keep out of reach of children
• No special temperature requirements — straightforward oral tablet formulation

As a responsible medicine distributor in Delhi, A.K. Pharma stores all medicines including Kryxana under manufacturer-recommended conditions ensuring product integrity for every supply to oncology centres and breast cancer clinics.

---

Manufacturer Information

Kryxana (Ribociclib) is manufactured by Novartis AG, a global pharmaceutical company with a major oncology portfolio. Ribociclib received FDA approval in March 2017 for HR-positive HER2-negative advanced breast cancer with an aromatase inhibitor — with subsequent approvals for the Fulvestrant combination (2018), premenopausal indication (2018), and updated OS-based labelling. A.K. Pharma supplies only genuine Kryxana sourced from authorized Novartis distributors.

---

Related Breast Cancer Medicines Available at A.K. Pharma

• Palbace (Palbociclib) — CDK4/6 inhibitor — longest clinical experience in class
• Ramiven (Abemaciclib) — CDK4/6 inhibitor — adjuvant approval, monotherapy approval
• Faslodex (Fulvestrant) — SERD — combined with Kryxana in MONALEESA-3
• Arimidex (Anastrozole) — aromatase inhibitor — combined with Kryxana first-line
• Aromasin (Exemestane) — steroidal aromatase inactivator
• Zoladex (Goserelin) — GnRH agonist for OFS in premenopausal women on Kryxana
• Browse all Cancer Medicines available at A.K. Pharma

---

Frequently Asked Questions

Q. What is Kryxana used for? Kryxana (Ribociclib) is used in combination with endocrine therapy for HR-positive HER2-negative locally advanced or metastatic breast cancer in pre/perimenopausal and postmenopausal women — in combination with aromatase inhibitors or Fulvestrant. More information available at MedlinePlus.

Q. What is the generic name of Kryxana? The generic name of Kryxana is Ribociclib. It is a selective CDK4/6 inhibitor manufactured by Novartis — the same active ingredient as the originator Kisqali.

Q. Why is Kryxana preferred in premenopausal women? Kryxana (Ribociclib) is the only CDK4/6 inhibitor to demonstrate significant overall survival benefit specifically in premenopausal women with HR-positive metastatic breast cancer — demonstrated in the MONALEESA-7 trial. No other CDK4/6 inhibitor has proven OS benefit in premenopausal patients. This unique evidence makes Kryxana the preferred CDK4/6 inhibitor for premenopausal HR-positive metastatic breast cancer in current guidelines.

Q. How many Phase 3 trials have shown OS benefit with Kryxana? Three — MONALEESA-2 (postmenopausal + aromatase inhibitor), MONALEESA-3 (postmenopausal + Fulvestrant — both first and second-line), and MONALEESA-7 (premenopausal + endocrine therapy + OFS). No other CDK4/6 inhibitor has OS benefit demonstrated in three separate Phase 3 trials across this breadth of patient populations.

Q. Why is ECG monitoring required with Kryxana but not other CDK4/6 inhibitors? Ribociclib prolongs the QTc interval — a unique pharmacological property among CDK4/6 inhibitors that Palbociclib and Abemaciclib do not share. QTc prolongation can in rare cases lead to potentially fatal ventricular arrhythmias. Mandatory ECG monitoring at baseline, Day 14 Cycle 1, and Day 1 Cycle 2 — along with electrolyte correction before starting — manages this risk safely in clinical practice.

Q. What dose of Kryxana is used and how is it taken? 600mg (three 200mg tablets) orally once daily for 21 days followed by 7 days off — repeating in 28-day cycles. Taken with or without food consistently. Avoid grapefruit. At approximately the same time each day.

Q. Can Kryxana be used with Fulvestrant? Yes — Kryxana + Fulvestrant (MONALEESA-3) is a standard of care for postmenopausal HR-positive HER2-negative advanced breast cancer in both first and second-line settings — with a proven median OS of 53.7 months. Both Kryxana and Faslodex (Fulvestrant) are available from A.K. Pharma.

Q. Is Kryxana available in India? Kryxana can be supplied to hospitals, oncology centres, and pharmacies across India through licensed pharmaceutical distributors. Contact A.K. Pharma — medicine distributor in Delhi — for availability and pricing.

Q. What is the price of Kryxana in India? Kryxana 200mg price in India varies by pack size. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current pricing and bulk supply rates.

Q. How to order Kryxana from A.K. Pharma? You can request a quote directly from this page, call us at 011 4172 6999, or WhatsApp us at +91 9810034827 with your requirements and we will respond promptly.

Q. Does A.K. Pharma supply Kryxana in bulk? Yes. A.K. Pharma supplies Kryxana in bulk to oncology centres, breast cancer clinics, hospitals, and pharmacies across Delhi and India. Contact us for bulk pricing and availability.

---

Why Order Kryxana from A.K. Pharma?

• Licensed medicine distributor in Delhi with all required drug licenses
• 100% genuine Kryxana sourced from authorized Novartis distributors
• Available alongside the full breast cancer CDK4/6 inhibitor and endocrine therapy portfolio — Palbace, Ramiven, Faslodex, Arimidex, Aromasin, Zoladex
• Bulk supply available for hospitals and oncology centres
• Prompt response to all quote requests
• Serving oncologists and breast cancer specialists across Delhi NCR and India

---

Contact A.K. Pharma for Kryxana Supply 📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052 📞 011 4172 6999 📱 WhatsApp: +91 9810034827 🌐 akpharma.in